DUBLIN–(BUSINESS THREAD)–The “Digital Marketing Trends in Human Immunodeficiency Virus (HIV)” the report has been added ResearchAndMarkets.com’s offers
Gilead’s Biktarvy.com had the highest traffic on branded HIV patient sites in the US from April 2021 to March 2022, with about 3,800,000 visits, followed by ViiV’s Dovato.com and Descovy. as of Gilead. The highest proportion of traffic to these sites originated from direct sources, followed by referrals. Websites for several brands, including Descovy, Cabenuva, Truvada and Pifeltro, had similar levels of high direct traffic (53-57%), while Janssen’s Symtuza.com had the lowest (34%).
For patient-branded sites, Gilead spent the most on DDA for Biktarvy.com at $20.5 million, followed by Gilead’s Descovy.com at $3.6 million and ViiV’s Dovato.com at $2. 3 million dollars. Descovy.com was supported by the highest paid keywords with approximately 10,200 keywords, followed by Biktarvy.com with approximately 5,900 keywords.
For branded HCP sites in the US, Gilead’s Descovyhcp.com had the highest number of hits with about 250,000 hits, followed by Gilead’s Biktarvyhcp.com (198,500 hits) and ViiV’s Dovatohcp.com (184,000 hits). The highest proportion of traffic to these sites originated from direct and organic sources. ViiV’s Rukobiahcp.com and Dovatohcp.com had the highest proportion of direct search traffic (66% and 61%, respectively). Gilead spent the most on DDA for Biktarvyhcp.com at about $212,000, followed by its Descovyhcp.com at about $67,000.
Between April 2021 and March 2022, the top 20 posts about HIV on social media by pharma interaction were from Gilead COMPASS Initiative’s Twitter and Instagram, ViiV Healthcare’s Instagram, and Gilead Science’s Twitter. Gilead’s HIV Answers is the only detected pharmacy app in the United States and had an estimated 730 downloads in 2021.
Most of the branded websites on EUCAN are located in Canada and are patient-oriented. Few generated significant traffic between April 2021 and March 2022. Gilead’s Bitarvy.ca and Descovy.ca achieved the highest traffic, with about 52,000 hits and 27,000 hits, respectively.
Between April 2021 and March 2022, most of the top 20 HIV social media posts by interaction in EUCAN from the pharmaceutical industry came from the MSD Europe Twitter account. No pharmacy HIV applications with notable downloads were detected in EUCAN.
scope
This report evaluates key digital marketing metrics for human immunodeficiency virus (HIV) pharmaceutical assets, including branded patient and healthcare professional (HCP) websites, mobile apps and social media accounts. Metrics include website traffic volume, engagement and feed, digital display advertising (DDA), paid search engine optimization (SEO), mobile app downloads and engagement with social media posts. Countries include the US, 4EU (Italy, France, Germany and Spain), UK and Canada (EUCAN)
Reasons to buy
Understand the competitive landscape of digital marketing in HIV, with a view of the main brand assets of patients and health professionals in different regions. See what tactics pharmaceutical companies are using to drive traffic to their HIV brand assets for patients and healthcare professionals, including DDA and paid SEO. Website traffic sources are those that drive the most visits to these assets, such as paid SEO, social media, or organic search. It compares the most important brand assets for patients based on how they address and support different patient needs. See which HIV pharma social media accounts are the most important. active and achieving maximum engagement See top pharmacy HIV mobile app deals in different regions
Key topics covered:
Executive Summary
US Patient Branded Websites US HCP Branded Websites US Digital Display Advertising and Search Engine Optimization US Mobile Apps & Social Media EUCAN Branded Websites EUCAN Mobile Apps & Social Media Appendix Methodology About authors Contact the publisher
For more information on this report, visit
[ad_2]
Source link
